• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

国家胆固醇教育计划(NCEP)利用新型电子技术(NEPTUNE)II 调查的结果以及近期 NCEP 写作小组建议下的治疗意义。

Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.

作者信息

Davidson Michael H, Maki Kevin C, Pearson Thomas A, Pasternak Richard C, Deedwania Prakash C, McKenney James M, Fonarow Gregg C, Maron David J, Ansell Benjamin J, Clark Luther T, Ballantyne Christie M

机构信息

Radiant Development, Chicago, Illinois, USA.

出版信息

Am J Cardiol. 2005 Aug 15;96(4):556-63. doi: 10.1016/j.amjcard.2005.04.019.

DOI:10.1016/j.amjcard.2005.04.019
PMID:16098311
Abstract

The most recent national survey of compliance with the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) guidelines was completed before ATP III and showed significant underachievement of low-density lipoprotein (LDL) cholesterol goals. The NCEP Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II was a national survey conducted in 2003. Of the 4,885 patients, 67% achieved their LDL cholesterol treatment goal, including 89%, 76%, and 57%, respectively, in the 0 or 1 risk factor, > or = 2 risk factors or coronary heart disease (CHD), and CHD risk equivalent categories. The percentage with triglyceride concentrations > or = 200 mg/dl (2.25 mmol/L) in each risk category who achieved their LDL cholesterol and non-high-density lipoprotein cholesterol goals was 64%, 52%, and 27%, respectively. Patients with diabetes (55%) and other CHD risk equivalents (40%) were less likely to have achieved their LDL cholesterol targets than those with CHD (62%). Of the 1,447 patients with cardiovascular disease, 75% could be classified as very high risk according to the new July 2004 NCEP Writing Group recommendations, and 17.8% of those at very high risk had an LDL cholesterol level of <70 mg/dl (<1.81 mmol/L). In conclusion, these results suggest improved lipid management compared with previous surveys. The largest treatment gaps were found for features new to ATP III as of July 2004, including goal achievement for patients with CHD risk equivalents and for non-high-density lipoprotein cholesterol targets. Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals.

摘要

最近一次关于遵循国家胆固醇教育计划(NCEP)成人治疗专家组(ATP)指南情况的全国性调查是在ATP III发布之前完成的,结果显示低密度脂蛋白(LDL)胆固醇目标的达标情况很不理想。NCEP利用新型电子技术进行的评估项目(NEPTUNE)II是2003年开展的一项全国性调查。在4885名患者中,67%实现了LDL胆固醇治疗目标,其中在无或有1个危险因素、≥2个危险因素或冠心病(CHD)以及CHD风险等同类别中,分别有89%、76%和57%的患者达标。在每个风险类别中,甘油三酯浓度≥200mg/dl(2.25mmol/L)且实现LDL胆固醇和非高密度脂蛋白胆固醇目标的患者比例分别为64%、52%和27%。糖尿病患者(55%)和其他CHD风险等同患者(40%)相比CHD患者(62%)更不容易实现LDL胆固醇目标。在1447名心血管疾病患者中,根据2004年7月NCEP写作组的新建议,75%可被归类为极高危,而在这些极高危患者中,17.8%的患者LDL胆固醇水平<70mg/dl(<1.81mmol/L)。总之,这些结果表明与之前的调查相比,血脂管理有所改善。在2004年7月ATP III新增的项目中发现了最大的治疗差距,包括CHD风险等同患者的目标达成情况以及非高密度脂蛋白胆固醇目标。NEPTUNE II中大多数(75%)心血管疾病患者会被视为极高危,是积极治疗以达到新的可选治疗目标的候选对象。

相似文献

1
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.国家胆固醇教育计划(NCEP)利用新型电子技术(NEPTUNE)II 调查的结果以及近期 NCEP 写作小组建议下的治疗意义。
Am J Cardiol. 2005 Aug 15;96(4):556-63. doi: 10.1016/j.amjcard.2005.04.019.
2
Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey.冠心病或风险等同情况女性患者血脂管理的治疗成功率降低:一项全国性调查结果
Am Heart J. 2006 Nov;152(5):976-81. doi: 10.1016/j.ahj.2006.05.013.
3
Non-high-density lipoprotein cholesterol: the forgotten therapeutic target.非高密度脂蛋白胆固醇:被遗忘的治疗靶点。
Am J Cardiol. 2005 Nov 7;96(9A):59K-64K; discussion 34K-35K. doi: 10.1016/j.amjcard.2005.08.009. Epub 2005 Oct 21.
4
Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.空军/德克萨斯冠状动脉粥样硬化预防研究对成人治疗小组第三次指南的启示。
Am J Cardiol. 2005 Dec 15;96(12):1674-80. doi: 10.1016/j.amjcard.2005.07.079. Epub 2005 Nov 2.
5
Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.在老年患者中,依折麦布联合他汀类药物持续治疗对改善血脂谱及实现低密度脂蛋白胆固醇目标的有效性:一项随机、双盲、安慰剂对照试验数据的亚组分析
Am J Geriatr Pharmacother. 2005 Dec;3(4):218-28.
6
New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III.美国国家胆固醇教育计划成人治疗组第三次报告中的新治疗选择。
Am J Manag Care. 2002 Sep;8(12 Suppl):S301-7.
7
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.近期临床试验对美国国家胆固醇教育计划成人治疗专家组第三次指南的影响。
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. doi: 10.1161/01.ATV.0000133317.49796.0E.
8
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.近期临床试验对美国国家胆固醇教育计划成人治疗专家组第三次指南的影响。
J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001.
9
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.在常规临床实践中,与其他他汀类药物相比,瑞舒伐他汀治疗的老年患者的低密度脂蛋白胆固醇(LDL-C)水平及LDL-C达标情况。
Am J Geriatr Pharmacother. 2007 Sep;5(3):185-94. doi: 10.1016/j.amjopharm.2007.10.002.
10
Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH).阿托伐他汀在患有严重血脂异常及心血管疾病或心血管疾病危险因素的女性中实现国家胆固醇教育计划低密度脂蛋白目标的疗效:女性阿托伐他汀胆固醇试验(WATCH)。
Am Heart J. 2001 Jun;141(6):949-56. doi: 10.1067/mhj.2001.115588.

引用本文的文献

1
Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.细胞色素 P450 3A4*22 和 3A5*3 基因型和多态性与高胆固醇血症患者对辛伐他汀反应的相关性。
PLoS One. 2022 Jul 15;17(7):e0260824. doi: 10.1371/journal.pone.0260824. eCollection 2022.
2
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target.载脂蛋白B与心血管疾病:生物标志物及潜在治疗靶点
Metabolites. 2021 Oct 8;11(10):690. doi: 10.3390/metabo11100690.
3
Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
ω-3 脂肪酸在他汀类药物治疗残余高甘油三酯血症患者中的疗效和安全性:一项随机、双盲、安慰剂对照临床试验。
Diabetes Metab J. 2020 Feb;44(1):78-90. doi: 10.4093/dmj.2018.0265. Epub 2019 Jun 20.
4
Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study.启动前蛋白转化酶枯草溶菌素 9 抑制剂的患者的临床特征和降脂治疗:一项全国性队列研究。
BMJ Open. 2019 Apr 1;9(4):e022702. doi: 10.1136/bmjopen-2018-022702.
5
Risk Factors Associated with Failure to Achieve the Low Density Lipoprotein Cholesterol Therapeutic Target in Patients with Acute Coronary Syndrome: A Longitudinal, Single Centre Investigation.急性冠状动脉综合征患者低密度脂蛋白胆固醇治疗目标未达标的相关危险因素:一项纵向单中心研究
High Blood Press Cardiovasc Prev. 2019 Feb;26(1):37-43. doi: 10.1007/s40292-019-00298-5. Epub 2019 Jan 25.
6
Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse.比较依折麦布与阿托伐他汀联合治疗与阿托伐他汀单药治疗调节血脂的疗效:系统评价和荟萃分析。
Lipids Health Dis. 2018 Oct 17;17(1):239. doi: 10.1186/s12944-018-0880-8.
7
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.对他汀类药物治疗的高甘油三酯水平和低高密度脂蛋白胆固醇水平患者的ω-3羧酸评估:STRENGTH试验的原理与设计
Clin Cardiol. 2018 Oct;41(10):1281-1288. doi: 10.1002/clc.23055. Epub 2018 Sep 28.
8
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.用于治疗杂合子家族性高胆固醇血症或有临床动脉粥样硬化性心血管疾病的成年患者的 PCSK9 抑制剂的预算影响分析。
Pharmacoeconomics. 2018 Jan;36(1):115-126. doi: 10.1007/s40273-017-0590-5.
9
Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL-C target goal achievement in China: Subgroup analysis of the Dyslipidemia International Study.医生特征和知识对中国血脂异常管理质量及低密度脂蛋白胆固醇(LDL-C)目标达成的影响:血脂异常国际研究的亚组分析
J Glob Health. 2017 Dec;7(2):020702. doi: 10.7189/jogh.07.020702.
10
A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations.当前可用非诺贝特和非诺贝酸制剂综述。
Cardiol Res. 2013 Apr;4(2):47-55. doi: 10.4021/cr270w. Epub 2013 May 9.